{
    "clinical_study": {
        "@rank": "141461", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate the ability of a slow-releasing formulation of neutral potassium\n      phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with\n      absorptive hypercalciuria.\n\n      II.  Evaluate the safety of this treatment. III.  Compare the efficacy of potassium\n      phosphate to that of potassium citrate."
        }, 
        "brief_title": "Phase III Randomized, Double-Blind Study of Potassium Phosphate Vs Potassium Citrate for Absorptive Hypercalciuria", 
        "condition": [
            "Hypercalciuria", 
            "Kidney Calculi"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Calculi", 
                "Hypercalciuria", 
                "Kidney Calculi"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double-blind study.  Patients are stratified by\n      participating institution.\n\n      Patients receive potassium phosphate or potassium citrate tablets twice a day for 3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics-- Absorptive hypercalciuria Intestinal hyperabsorption of\n        calcium, i.e.: Exaggerated calciuric response to oral calcium load OR Fractional\n        calcium-47 absorption greater than 0.61 Calciuria greater than 200 mg/day on random and\n        calcium-restricted diet Normal or high fasting urinary calcium Normal serum calcium Normal\n        serum parathyroid hormone No primary hyperparathyroidism At least 1 calcium oxalate stone\n        within the past 3 years No struvite or carbonate apatite stones No noncalcareous stones No\n        numerous stones making precise quantitation difficult No renal tubular acidosis\n        --Prior/Concurrent Therapy-- No concurrent drug therapy for nephrolithiasis --Patient\n        Characteristics-- Creatinine clearance at least 0.7 mL/min per kilogram No hyperkalemia No\n        hyperphosphatemia No urinary tract infection Other: No predisposition to hyperkalemia,\n        including concurrent use of the following drugs: Potassium-sparing diuretics\n        Angiotensin-converting enzyme inhibitors Nonsteroidal anti-inflammatory drugs No active\n        peptic ulcer disease No chronic diarrhea"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "300", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004284", 
            "org_study_id": "199/11703", 
            "secondary_id": "UTSMC-039510400"
        }, 
        "intervention": [
            {
                "intervention_name": "potassium citrate", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "potassium phosphate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Potassium phosphate", 
                "Potassium Citrate"
            ]
        }, 
        "keyword": [
            "hypercalciuria", 
            "nephrolithiasis", 
            "rare disease", 
            "renal and genitourinary disorders"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Texas", 
            "last_name": "Charles Y. C. Pak", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004284"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                    "agency_class": "NIH"
                }, 
                {
                    "agency": "University of Texas", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 1995", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2000"
    }, 
    "geocoordinates": {}
}